Physician profile
Farron C Bennett
NPI 1518032044
$5,460.26
in general payments reported to CMS, 2019-2025
32 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,203 · 2023: $1,812 · 2024: $2,143 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,257.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $878.25 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $654.82 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $468.60 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $458.77 | 2022-2025 | Verquvo, Gardasil 9, Vaxelis |
| Pfizer INC. | $431.95 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.72 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $289.31 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $252.29 | 2022-2024 | Trelegy Ellipta, Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $165.15 | 2022 | |
| Exact Sciences Corporation | $162.40 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $162.20 | 2022-2023 | Trintellix |
| Amneal Pharmaceuticals LLC | $154.25 | 2023-2024 | Unithroid |
| Astellas Pharma US INC | $139.68 | 2023-2024 | Veozah |
| Amgen INC. | $116.93 | 2023-2025 | Repatha, Otezla, Otezla |
| Mylan Specialty L.P. | $109.55 | 2022-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $85.83 | 2022-2024 | Aplenzin, Wellbutrin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.13 | 2022-2023 | Xifaxan, Trulance |
| Antares Pharma, INC. | $69.35 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $63.40 | 2024 | Rexulti |
| Lundbeck LLC | $57.65 | 2024-2025 | Vyepti |
| Baxter Healthcare | $52.19 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Tolmar, INC. | $51.91 | 2024 | |
| Halozyme INC | $33.14 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $32.61 | 2023-2024 | Austedo Xr |
| Paratek Pharmaceuticals, INC. | $28.48 | 2024-2025 | Nuzyra |
| Abbott Laboratories | $22.95 | 2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $22.16 | 2023 | Auvelity |
| Janssen Pharmaceuticals, INC | $20.11 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.63 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $16.86 | 2022 | |
| Phadia US INC. | $15.15 | 2022 | |
| Shield Therapeutics INC | $13.84 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farron Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.